Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Phase 3 Terminated 169 enrolled Endo USA Inc., a Keenova Therapeutics Company

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.

Timeline

Start: 2008-09
Primary completion: 2011-02
Completion: 2011-06

Publications

Chieffo C, Cook D, Xiang Q, Frohman LA. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab. 2013 Oct;98(10):4047-54. doi: 10.1210/jc.2013-2262. Epub 2013 Aug 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Octreotide	Peptide	10 mg	Subcutaneous
Comparator	Octreotide	Peptide	20 mg	Subcutaneous
Comparator	Octreotide	Peptide	30 mg	Subcutaneous
Comparator	Octreotide	Peptide	40 mg	Subcutaneous
Comparator	Octreotide	Peptide	84 mg	Subcutaneous

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Summary

Timeline

Publications

Drugs

Indications